Physician profile

Elena Gelfand

Sacramento, CA

NPI 1154342343

$1,466.95

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$658.26

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Astrazeneca Pharmaceuticals LP $360.67 2019-2022
Amgen INC. $299.82 2024 Tavneos
Vifor Pharma, INC. $205.64 2019
Calliditas Therapeutics US INC. $132.48 2023 Tarpeyo
Alexion Pharmaceuticals, INC. $124.99 2023
Aurinia Pharma U.S., INC. $123.97 2022
Baxter Healthcare $101.57 2019
Novartis Pharmaceuticals Corporation $100.97 2024
Horizon Therapeutics Plc $16.84 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Elena Gelfand

$1,466.95

in general payments reported 2019-2025

Years
2019-2024
Top company
Astrazeneca Pharmaceuticals LP

https://glasscript.com/doctor/51639/elena-gelfand

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.